Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermalin Diabetes LLC

Three takes on next-generation insulin analogs

This article was originally published in Start Up

Executive Summary

Thermalin Diabetes LLC is developing candidates aimed at three separate segments of the insulin analog market, the first, a rapid-acting, ultra-concentrated insulin will complete preclinical proof-of-concept studies this spring. A second, ultra-rapid-acting insulin analog is designed to make mealtime dosing more effective. Finally, Thermalin has figured out a way to make both basal and rapid-acting insulins that are stable in the heat, potentially enabling important new ways to get insulin to patients.

You may also be interested in...



With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology

BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.

Patheon Tightens The Supply Chain To Transform Pharma Outsource Manufacturing

Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.

Polaris Stays Disciplined For Breakthroughs: An Interview With Alan Crane

The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel